At present, aromatase inhibitors/inactivators, SERMs, selective ER degrader/down-regulator (SERD), and cyclin-dependent kinases 4/6 (CDK4/6) inhibitors are the first-line standard of care for patients with HR-positive and HER2-negative breast cancers [153]. Here, CDK4 is linked to breast carcinoma.